← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Acucela, Inc.
Bothell, WA
$1,833,212
Total funding
3
Grants
Funding over time
peak $545K · FY2007–22$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
FDA$1,633,917 · 1
NIH$199,295 · 2
By mechanism
R01$1,633,917 · 1
R43$199,295 · 2
Investigators at Acucela, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019)$545,000
R01 · FY2021 · FD
A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019)$545,000
R01 · FY2022 · FD
A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019)$543,917
R01 · FY2020 · FD
In Vitro Assay to Assess Chemical Toxicity in Retinal Primary Cell Cultures$100,000
R43 · FY2007 · ES
Identifying Cytoprotectants for Photoreceptors and RPE Cells to Treat Dry AMD$99,295
R43 · FY2007 · EY